(Press-News.org) EBC-129 is an antibody-drug conjugate (ADC) that selectively targets a novel, tumour-specific N-glycosylated epitope found on both CEACAM5 and CEACAM6.
The expansion cohort for pancreatic ductal adenocarcinoma (PDAC) in the ongoing Phase 1 trial has completed enrolment. Notably, 82% of patients had tumours expressing the antigen at levels considered treatable with EBC-129.
EBC-129 demonstrated positive overall response rates and prolonged progression-free survival in PDAC patients that have been heavily pre-treated, including those that have received prior treatment with standard of care (SoC) typically containing taxanes.
The US FDA also recently granted Fast Track Designation for EBC-129 in the treatment of PDAC patients.
Singapore, 3 June 2025 – The Experimental Drug Development Centre (EDDC), Singapore’s national platform for drug discovery and development, has announced the presentation of updated clinical data for the ongoing Phase 1 trial for EBC-129 at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
EBC-129 is a first-in-class antibody drug conjugate (ADC) targeting a novel, tumour-specific N256-glycosylated epitope on CEACAM5 and CEACAM6. The updated findings showed promising efficacy data from 21 heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patients across the dose escalation and the dose expansion portions of the Phase 1 study. Patients received EBC-129 at doses between 1.8 and 2.2 mg/kg, given once every 3 weeks. 17 out of 21 patients (81%) of the patients had received prior treatment with taxanes. 82% of patients had tumours which expressed the EBC-129 antigen at ≥1% at 3+ intensity and were therefore considered treatable. The overall response rates (ORRs) were 25% and 20%, with disease control rates (DCRs) of 87.5% and 63.6% and progression-free survival (PFS) of 19 and 12 weeks for 1.8 mg/kg and 2.2 mg/kg, respectively.
“Pancreatic adenocarcinoma remains one of the most challenging cancers to treat, particularly in the metastatic setting where resistance to standard therapies is common. The clinical signals observed with EBC-129 in refractory pancreatic adenocarcinoma, including tolerability, prolonged disease control and a confirmed response in a heavily pre-treated patient, are encouraging and clinically meaningful. Continued prioritisation of biology-guided trials targeting EBC-129 will be key to sustaining momentum in this important therapeutic effort,” said Assistant Professor Robert W. Lentz, MD, Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz School of Medicine.
This presentation follows the recent Fast Track Designation granted by the U.S. FDA for EBC-129 in the treatment of PDAC patients. This designation supports EDDC’s efforts to accelerate the advancement of the programme through increased regulatory engagement and the potential for expedited review pathways.
Other Results to Date
The dose escalation study of the Phase 1 trial was open to all patients, while the ongoing dose expansion study comprises of three cohorts in PDAC, gastroesophageal adenocarcinoma (GEA) and tumour-agnostic patients with other immunohistochemistry (IHC)-positive solid tumours. Recruitment for the GEA and IHC-positive cohorts is still ongoing.
EBC-129 showed a manageable safety profile in the 58 patients treated so far, with uncomplicated neutropenia and infusion-related reactions as the main treatment-related adverse events (TRAEs) observed.
The EBC-129 antigen was also found to be highly expressed, with 52% to 100% of tumour tissues assessed during the trial showing moderate to high expression levels of ≥20% at 2+ and/or 3+. This included samples from gastroesophageal, appendiceal, colorectal and lung cancer patients, making EBC-129 a potentially viable treatment option for these cancers.
“We have seen encouraging signs of efficacy of EBC-129 as a single-agent therapy, even in heavily pre-treated patients with metastatic pancreatic cancer. This, combined with the observed safety profile, underscores the promise of EBC-129 as a possible treatment option for PDAC patients. As a first-in-class ADC that targets both CEACAM5 and CEACAM6, EBC-129 has also shown potential against a range of other solid tumours, and we look forward to expanding clinical evaluations with the ongoing dose expansion cohorts and accelerating the development of EBC-129 to address critical unmet needs in cancer,” said Professor Damian O’Connell, CEO of EDDC.
About EBC-129
EBC-129 is an ADC that targets a tumour-specific N256-glycosylation site conserved on CEACAM5 and CEACAM6. CEACAM5 and CEACAM6 are known to have functional importance in tumour formation, migration and metastasis. In the ongoing trial, the tumour-specific marker is found to be widely expressed in multiple solid tumour types, including gastric, oesophageal, pancreatic, lung, colorectal, and appendiceal cancers, based on an analytically validated immunohistochemistry (IHC) assay. The payload used in EBC-129 is monomethyl auristatin E (MMAE), which has been extensively tested and approved for clinical use in other marketed ADCs, and has demonstrated synergy with PD-1 inhibitors. The ongoing Phase 1 trial of EBC-129 is assessing the safety and tolerability of EBC-129 as a single agent and in combination with pembrolizumab in patients with advanced solid tumours. Enrolment for the PDAC cohort in the Phase 1 dose expansion study is now complete, while recruitment continues for the gastroesophageal adenocarcinoma (GEA) and IHC-positive cohorts.
For information about the trial, please visit Clinicaltrial.gov, trial identifier NCT05701527.
About the Experimental Drug Development Centre
The Experimental Drug Development Centre (EDDC) is Singapore’s national platform for drug discovery and development, formed from the integration of the Experimental Therapeutics Centre (ETC), Drug Discovery and Development (D3), and Experimental Biotherapeutics Centre (EBC) in 2019. EDDC aims to develop therapeutics and diagnostics that save and improve the lives of patients in Singapore, Asia and around the world. Hosted by the Agency for Science, Technology and Research (A*STAR), EDDC works collaboratively with public sector and industry partners to translate the great science arising from Singapore’s biomedical and clinical sciences R&D into innovative healthcare solutions. For more information about EDDC, please visit www.eddc.sg.
END
Experimental Drug Development Centre announces the presentation of updated data from the phase 1 study of antibody-drug conjugate EBC-129 at the 2025 Annual Meeting of the American Society of Clinical
2025-06-03
ELSE PRESS RELEASES FROM THIS DATE:
African swine fever not recently imported to Europe, has been around for years
2025-06-03
A new study in Genome Biology and Evolution, published by Oxford University Press, finds that the African Swine Fever virus, currently circulating in Europe, is not the result of a recent introduction. Instead, the virus has been present in the region since 2007. Its current dramatic spread appears to be driven largely by people within Europe traveling longer distances.
African Swine Fever virus is a highly virulent DNA virus that causes a severe hemorrhagic disease of the same name affecting both domestic pigs and wild boars. The disease is characterized by high mortality rates, leading to significant economic losses in the pork industry. According to estimates ...
APA calls for guardrails, education, to protect adolescent AI users
2025-06-03
The effects of artificial intelligence on adolescents are nuanced and complex, according to a report from the American Psychological Association that calls on developers to prioritize features that protect young people from exploitation, manipulation and the erosion of real-world relationships.
“AI offers new efficiencies and opportunities, yet its deeper integration into daily life requires careful consideration to ensure that AI tools are safe, especially for adolescents,” according to the report, entitled “Artificial Intelligence and Adolescent Well-being: An APA ...
Wendelstein 7-X sets new performance records in nuclear fusion research
2025-06-03
On the path toward a fusion power plant, stellarators are among the most promising concepts. In the future, they could generate usable energy by fusing light atomic nuclei. This reaction must take place in a plasma — a hot gas of ionized particles heated to many tens of millions of degrees Celsius. Stellarators use magnetic confinement to hold the plasma: the plasma is trapped by a complex and powerful magnetic field, floating inside a donut-shaped vacuum chamber. With Wendelstein 7-X (W7-X), the Max Planck Institute for Plasma Physics (IPP) in Greifswald, with support from the European fusion consortium EUROfusion, is operating the world's ...
Brain connections at 3 months predict infant emotional development
2025-06-03
PITTSBURGH, Pennsylvania, USA, 3 June 2025 – In a comprehensive Genomic Press research article, scientists have uncovered remarkable insights into how the earliest brain connections shape infant emotional development, potentially offering new ways to identify children at risk for future behavioral and emotional challenges.
The groundbreaking study, led by Dr. Yicheng Zhang and Dr. Mary L. Phillips at the University of Pittsburgh School of Medicine, examined 95 infant-caregiver pairs using advanced brain imaging techniques. Researchers discovered that the microstructure of white matter ...
Listening to life: Speech technology transforms clinical research
2025-06-03
ATLANTA, Georgia, USA, 3 June 2025 – In a comprehensive Genomic Press interview published today in Psychedelics, Dr. Deanna M. Kaplan reveals how her journey from journalism student to clinical psychologist led to revolutionary advances in capturing human experiences through voice technology. As Assistant Professor at Emory University School of Medicine and Director of Health Technologies for Spiritual Health at Emory Healthcare, Dr. Kaplan has transformed how researchers understand the impact of clinical ...
ECT sessions shape depression treatment outcomes
2025-06-03
HEFEI, Anhui, China, 3 June 2025 – In a comprehensive peer-reviewed Genomic Press Thought Leaders Invited Review, researchers have unveiled critical insights into how the number of electroconvulsive therapy (ECT) sessions influences treatment outcomes for depression, potentially transforming clinical decision-making for one of psychiatry's most effective yet controversial treatments.
The review, published in Brain Medicine, synthesizes decades of research to address a fundamental question that has long puzzled clinicians: How many ECT sessions are optimal for treating severe depression while minimizing cognitive side effects?
"ECT is like a powerful ...
Psilocybin enters gastroenterology: First-ever psychedelic study targets treatment-resistant IBS
2025-06-03
BOSTON, Massachusetts, USA, 3 June 2025 – In a comprehensive Genomic Press Interview published today, Dr. Erin E. Mauney reveals how her pioneering research brings psychedelic medicine into gastroenterology for the first time, potentially transforming treatment for millions suffering from intractable irritable bowel syndrome (IBS).
The assistant professor of pediatrics at Tufts University, who maintains a research appointment at Massachusetts General Hospital, leads the first clinical trial examining psilocybin's effects on treatment-resistant IBS. Her work addresses a critical gap in medicine: the substantial population ...
Renowned psychiatrist illuminates biological roots of mental illness through pioneering research
2025-06-03
MILANO, Italy, 3 June 2025 – In a comprehensive Genomic Press Interview published in Brain Medicine, Professor Francesco Benedetti shares his transformative journey from confronting childhood awareness of mental illness to becoming a leading figure in psychiatric research. As founder and leader of the Psychiatry & Clinical Psychobiology research unit at IRCCS Ospedale San Raffaele, Dr. Benedetti has dedicated decades to reclaiming psychiatry's rightful place within medical science.
Professor ...
Ancient collagen can help identify a “wombat the size of a hippo” in the fossil record
2025-06-03
What happened to all the megafauna? From moas to mammoths, many large animals went extinct between 50 and 10,000 years ago. Learning why could provide crucial evidence about prehistoric ecosystems and help us understand future potential extinctions. But surviving fossils are often too fragmented to determine the original species, and DNA is not always recoverable, especially in hot or damp environments. Now scientists have isolated collagen peptide markers which allow them to identify three key megafauna ...
Being in nature can help people with chronic back pain manage their condition
2025-06-03
ing time in or around nature can provide people suffering from chronic lower back pain with a degree of escapism that helps them better manage their physical discomfort, a new study has shown.
The research, published in The Journal of Pain, is the first of its kind to ask people experiencing chronic lower back pain – in some cases for almost 40 years – about the role nature plays in any coping strategies they employ to help manage their condition.
The researchers found that people able to get out in nature said it enabled them to connect with ...